Novo Nordisk rises as Q3 Wegovy pill sales, profit beat forecasts

Novo Nordisk A/S

04/11/2026 08:23

Updates share move, adds details on Q3 numbers, additional analyst comment, milestone
** Shares in Novo Nordisk NOVOb.CO rise 6% after the Danish drugmaker posted better-than-expected Q3 results and hiked its full-year sales and profit outlook
** Its third-quarter sales of 79.20 billion Danish crowns ($11.90 billion) were 8% ahead of market expectations and adjusted earnings of 31.72 billion crowns beat forecasts by 12%
** Sales of Wegovy pill reached 5.39 billion crowns in the quarter, 17% above expectations
 ** Jefferies says favourable pricing and rebate adjustments boosted quarterly sales, adding that injectable Wegovy would have missed its estimates without this benefit
 ** Novo raised its 2026 adjusted sales and operating profit growth forecasts to between a 2% decline and a 2% increase, from a previous range of a 6% decline to flat growth, citing stronger expectations for GLP-1 drug sales
 ** J.P. Morgan says in a note the stronger-than-expected results and upgraded guidance imply potential increases of around 3% to consensus estimates for both sales and operating profit
** Novo shares are on track for their best day since April 
     
     
($1 = 6.6544 Danish crowns)

(Reporting by Jesus Calero)
((jesus.calero@thomsonreuters.com))